HENLIUS Shares Surge on Global First for its Key Cancer Drug

Stock News06-12 13:58

HENLIUS (SEHK: 02696) shares rose over 8% in trading today.

At the time of writing, the stock was up 8.52% to HK$61.75, with a trading turnover exceeding HK$42.21 million.

The significant move follows a major regulatory announcement from the company. HENLIUS recently declared that the New Drug Application for an additional indication of its self-developed anti-PD-1 monoclonal antibody, HANSIZHUANG® (serplulimab, known as Hetronifly® in Europe), has been formally approved by China's National Medical Products Administration via a priority review pathway.

The approval covers the use of the drug in combination with oxaliplatin and tegafur for the neoadjuvant treatment of operable gastric cancer in patients with PD-L1 expression CPS≥5, followed by monotherapy as an adjuvant treatment post-surgery.

This regulatory milestone establishes HANSIZHUANG® as the first and only anti-PD-1 monoclonal antibody globally approved for perioperative treatment of gastric cancer, addressing a significant unmet clinical need in this area.

Furthermore, this treatment regimen enables postoperative immunotherapy monotherapy to replace traditional adjuvant chemotherapy. This approach has demonstrated significantly improved efficacy while effectively avoiding the toxic side effects commonly associated with chemotherapy.

The drug's commercial value and future growth potential are now being reassessed by the market. This development is expected to have a transformative impact on the treatment landscape for gastric cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115461891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 13:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115461891","market":"us","top_or_hot":-1,"title":"HENLIUS Shares Surge on Global First for its Key Cancer Drug","media":"Stock News","content":"<p><b>HENLIUS</b> (<b>SEHK: 02696</b>) shares rose over 8% in trading today.<br><br>At the time of writing, the stock was up 8.52% to HK$61.75, with a trading turnover exceeding HK$42.21 million.<br><br>The significant move follows a major regulatory announcement from the company. <b>HENLIUS</b> recently declared that the New Drug Application for an additional indication of its self-developed anti-PD-1 monoclonal antibody, HANSIZHUANG® (serplulimab, known as Hetronifly® in Europe), has been formally approved by China's National Medical Products Administration via a priority review pathway.<br><br>The approval covers the use of the drug in combination with oxaliplatin and tegafur for the neoadjuvant treatment of operable gastric cancer in patients with PD-L1 expression CPS≥5, followed by monotherapy as an adjuvant treatment post-surgery.<br><br>This regulatory milestone establishes HANSIZHUANG® as the first and only anti-PD-1 monoclonal antibody globally approved for perioperative treatment of gastric cancer, addressing a significant unmet clinical need in this area.<br><br>Furthermore, this treatment regimen enables postoperative immunotherapy monotherapy to replace traditional adjuvant chemotherapy. This approach has demonstrated significantly improved efficacy while effectively avoiding the toxic side effects commonly associated with chemotherapy.<br><br>The drug's commercial value and future growth potential are now being reassessed by the market. This development is expected to have a transformative impact on the treatment landscape for gastric cancer.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS Shares Surge on Global First for its Key Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS Shares Surge on Global First for its Key Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-12 13:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>HENLIUS</b> (<b>SEHK: 02696</b>) shares rose over 8% in trading today.<br><br>At the time of writing, the stock was up 8.52% to HK$61.75, with a trading turnover exceeding HK$42.21 million.<br><br>The significant move follows a major regulatory announcement from the company. <b>HENLIUS</b> recently declared that the New Drug Application for an additional indication of its self-developed anti-PD-1 monoclonal antibody, HANSIZHUANG® (serplulimab, known as Hetronifly® in Europe), has been formally approved by China's National Medical Products Administration via a priority review pathway.<br><br>The approval covers the use of the drug in combination with oxaliplatin and tegafur for the neoadjuvant treatment of operable gastric cancer in patients with PD-L1 expression CPS≥5, followed by monotherapy as an adjuvant treatment post-surgery.<br><br>This regulatory milestone establishes HANSIZHUANG® as the first and only anti-PD-1 monoclonal antibody globally approved for perioperative treatment of gastric cancer, addressing a significant unmet clinical need in this area.<br><br>Furthermore, this treatment regimen enables postoperative immunotherapy monotherapy to replace traditional adjuvant chemotherapy. This approach has demonstrated significantly improved efficacy while effectively avoiding the toxic side effects commonly associated with chemotherapy.<br><br>The drug's commercial value and future growth potential are now being reassessed by the market. This development is expected to have a transformative impact on the treatment landscape for gastric cancer.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000306685.HKD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","start_time":0,"source_url":"","article_id":"1115461891","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115461891","pubTimestamp":1781243906,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (SEHK: 02696) shares rose over 8% in trading today.At the time of writing, the stock was up 8.52% to HK$61.75, with a trading turnover exceeding HK$42.21 million.The significant move follows...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","02696":"复宏汉霖","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK4585":"ETF&股票定投概念","BK1161":"生物科技","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC"},"translate_title":"复宏汉霖关键抗癌药物全球首创股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1,"VXUS":1},"content_text":"HENLIUS (SEHK: 02696) shares rose over 8% in trading today.At the time of writing, the stock was up 8.52% to HK$61.75, with a trading turnover exceeding HK$42.21 million.The significant move follows a major regulatory announcement from the company. HENLIUS recently declared that the New Drug Application for an additional indication of its self-developed anti-PD-1 monoclonal antibody, HANSIZHUANG® (serplulimab, known as Hetronifly® in Europe), has been formally approved by China's National Medical Products Administration via a priority review pathway.The approval covers the use of the drug in combination with oxaliplatin and tegafur for the neoadjuvant treatment of operable gastric cancer in patients with PD-L1 expression CPS≥5, followed by monotherapy as an adjuvant treatment post-surgery.This regulatory milestone establishes HANSIZHUANG® as the first and only anti-PD-1 monoclonal antibody globally approved for perioperative treatment of gastric cancer, addressing a significant unmet clinical need in this area.Furthermore, this treatment regimen enables postoperative immunotherapy monotherapy to replace traditional adjuvant chemotherapy. This approach has demonstrated significantly improved efficacy while effectively avoiding the toxic side effects commonly associated with chemotherapy.The drug's commercial value and future growth potential are now being reassessed by the market. This development is expected to have a transformative impact on the treatment landscape for gastric cancer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115461891","isCrawlerRequest":true}